✦ LIBER ✦

Can We and Should We Improve on Frontline Imatinib Therapy for Chronic Myeloid Leukemia?

✍ Scribed by Carmen Fava; Giuseppe Saglio

Book ID: 117822205
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 219 KB
Volume: 47
Category: Article
ISSN: 1532-8686
DOI: 10.1053/j.seminhematol.2010.06.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Minimal Residual Disease and Discontinua

Minimal Residual Disease and Discontinuation of Therapy in Chronic Myeloid Leukemia: Can We Aim at a Cure?

✍ Melo, J. V.; Ross, D. M. 📂 Article 📅 2011 🏛 American Society of Hematology 🌐 English ⚖ 290 KB

Double Philadelphia-chromosome: a resist

Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia

✍ L. Otero; M. H Ornellas; J. Dobbin; T. De Souza Fernandez 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB

Imatinib as the first-line treatment of

Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials?

✍ Daniela Zackova; Hana Klamova; Ladislav Dusek; Jan Muzik; Katerina Machova Polak 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB 👁 3 views

Impact of imatinib therapy on the use of

Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia

✍ Sergio A. Giralt; Mukta Arora; John M. Goldman; Stephanie J. Lee; Richard T. Maz 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 540 KB

Dasatinib, even at low doses, is an effe

Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients

✍ Giuseppe Visani; Massimo Breccia; Antonella Gozzini; Giorgina Specchia; Enrico M 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 640 KB

No significance of derivative chromosome

No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia

✍ Dong Hwan (Dennis) Kim; Gizelle Popradi; Lakshmi Sriharsha; Suzanne Kamel-Reid; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 486 KB